Stony Brook Heart Institute Administers World’s First Plozasiran Treatment for Rare Lipid Disease

Stony Brook Heart Institute’s Center for Advanced Lipid Management has achieved a historic global milestone, becoming the first center in the world to administer a commercial dose of plozasiran, the newly approved RNA-interference therapy for…